Pfizer Inc. $PFE Shares Bought by Nexus Investment Management ULC

Nexus Investment Management ULC raised its stake in Pfizer Inc. (NYSE:PFE) by 2.0% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 991,225 shares of the biopharmaceutical company’s stock after purchasing an additional 19,700 shares during the quarter. Pfizer comprises about 3.4% of Nexus Investment Management ULC’s investment portfolio, making the stock its 13th biggest position. Nexus Investment Management ULC’s holdings in Pfizer were worth $24,682,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the stock. Franklin Resources Inc. lifted its position in shares of Pfizer by 47.8% during the third quarter. Franklin Resources Inc. now owns 25,070,148 shares of the biopharmaceutical company’s stock worth $638,787,000 after purchasing an additional 8,108,887 shares in the last quarter. Neuberger Berman Group LLC lifted its position in shares of Pfizer by 203.8% during the third quarter. Neuberger Berman Group LLC now owns 9,012,811 shares of the biopharmaceutical company’s stock worth $229,346,000 after purchasing an additional 6,045,763 shares in the last quarter. Ameriprise Financial Inc. lifted its position in shares of Pfizer by 48.2% during the third quarter. Ameriprise Financial Inc. now owns 18,373,140 shares of the biopharmaceutical company’s stock worth $468,174,000 after purchasing an additional 5,978,927 shares in the last quarter. AQR Capital Management LLC lifted its position in shares of Pfizer by 120.9% during the third quarter. AQR Capital Management LLC now owns 9,505,615 shares of the biopharmaceutical company’s stock worth $230,986,000 after purchasing an additional 5,202,884 shares in the last quarter. Finally, Amundi lifted its position in shares of Pfizer by 10.8% during the third quarter. Amundi now owns 41,490,929 shares of the biopharmaceutical company’s stock worth $1,096,380,000 after purchasing an additional 4,043,413 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently issued reports on PFE. Bank of America reduced their price target on shares of Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a research report on Monday, December 15th. Cantor Fitzgerald reissued a “neutral” rating and set a $27.00 price target on shares of Pfizer in a research report on Wednesday, February 4th. Zacks Research raised shares of Pfizer from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 24th. Daiwa Securities Group cut shares of Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price target on the stock. in a research report on Thursday, February 12th. Finally, Morgan Stanley set a $27.00 target price on shares of Pfizer and gave the stock a “positive” rating in a research note on Tuesday, March 17th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, thirteen have assigned a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $28.19.

Pfizer Stock Down 2.6%

PFE stock opened at $27.10 on Wednesday. The company’s 50 day moving average price is $27.14 and its 200 day moving average price is $25.89. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.87 and a current ratio of 1.16. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $28.75. The firm has a market capitalization of $154.07 billion, a price-to-earnings ratio of 19.92 and a beta of 0.43.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, beating the consensus estimate of $0.57 by $0.09. The company had revenue of $17.56 billion for the quarter, compared to analyst estimates of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The firm’s revenue was down 1.2% on a year-over-year basis. During the same period in the prior year, the firm posted $0.63 earnings per share. On average, equities research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer filed a new Phase 1 study (PF-07328948), signaling continued pipeline investment and R&D momentum that supports longer-term growth prospects. Pfizer’s New Phase 1 PF-07328948 Study Signals Ongoing Pipeline Investment
• Positive Sentiment: Optimistic retail/analyst takes: at least one bullish piece argues PFE looks undervalued and could be a strong buy over a multi-year horizon, which can support investor appetite for the stock on dips. Prediction: In 5 Years, You’ll Wish You Bought Pfizer Stock Today
• Neutral Sentiment: Market correlation: some coverage notes today’s action is tied to broader S&P 500 moves rather than company-specific news, which can amplify price swings independent of fundamentals. Pfizer Inc. Market Action Tied To S&P 500 Index Movement
• Neutral Sentiment: Feature pieces weigh reasons to watch PFE while advising caution — helpful context for investors assessing valuation versus near-term risks. 2 Reasons to Watch PFE and 1 to Stay Cautious
• Neutral Sentiment: Sector competitive landscape: coverage of the expanding “diabesity” (GLP‑1) market highlights big opportunities for peers like Lilly and Novo Nordisk — an indirect signal that competition and missed participation in the category could pressure Pfizer’s long‑term growth narrative. The $190 Billion ‘Diabesity’ Market Is Set to Explode. Lilly and Novo Face These Stock Catalysts.
• Negative Sentiment: Clinical setback: Pfizer and its COVID‑19 vaccine partner paused an updated‑shot trial, which prompted immediate selling pressure and raises short‑term uncertainty about their COVID franchise strategy. Why Is Pfizer Stock Dropping Tuesday?
• Negative Sentiment: Policy risk: reports that a Washington proposal could impose steep tariffs (or a 100% framework) on drugmakers without pricing agreements added regulatory and political risk that can pressure valuations in the near term. Why Is Pfizer Stock Dropping Tuesday?
• Negative Sentiment: Market reaction note: headline summaries show the stock has moved lower amid these combined factors, which explains today’s downward price action versus recent highs. Pfizer (PFE) Stock Drops Despite Market Gains: Important Facts to Note

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.